When we administered a CD8-specific depleting mAb in the memory phase before re-challenging mice with tumor cells (Figure 3F), mice lacking CD8+ T cells were unable to control the tumor re-challenge, whereas mice treated with an isotype-matched mAb remained tumor free until day 100 (Figure 3G). Here, CD8A is linked to neoplasm.